Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising prelimin
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to
Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidat
Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?
12:31pm, Friday, 29'th May 2026
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
A Look at Avis Budget Group Inc (CAR) After 5.9% Gain -- GF Value $130.88 vs Price $174.88
06:58pm, Thursday, 28'th May 2026
On May 28, 2026, Avis Budget Group Inc (CAR) shares rose by 5.9%, bringing the current price to $174.88. This latest movement comes amid a 52-week range that ha
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
02:55pm, Thursday, 28'th May 2026
Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.
Avis Budget Group Announces Pricing of $300 Million of Senior Notes
05:21pm, Wednesday, 27'th May 2026
PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Bu
TTEC vs. Avis Budget: Which Turnaround Stock is Better Positioned?
12:50pm, Wednesday, 27'th May 2026
TTEC's AI-driven turnaround, improving free cash flow and a stronger liquidity position it ahead of CAR's volatile recovery efforts.
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
07:45am, Wednesday, 27'th May 2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therape
Avis Budget Group Announces Intention to Offer $300 Million of Senior Notes
07:30am, Wednesday, 27'th May 2026
PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Bu
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
04:03am, Wednesday, 27'th May 2026
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session modera
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st
HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announc
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell
Avis Budget's Pricing Recovery Signals Improving Industry Discipline
10:25am, Tuesday, 19'th May 2026
CAR's pricing rebound and tighter fleet management are boosting utilization and improving depreciation trends.
